News
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks.
Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...
1d
TipRanks on MSNHims & Hers Health Stock Soars Amid Investor BuzzHims & Hers Health ( ($HIMS) ) has risen by 21.11%. Read on to learn why. Hims & Hers Health has experienced a notable 21.11% ...
Hims & Hers (NYSE:HIMS) stock slips as U.S. lawmakers seek FDA action against copycat versions of weight loss drugs from Novo ...
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...
HIMS stock up 16% on Wednesday, continuing month-long gains. Novo Nordisk ends partnership, cites misleading marketing and safety concerns.
4d
Money Talks News on MSNWegovy Fallout: How Novo’s Exit Hits Your Wallet and WaistlineNovo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from ...
We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...
An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...
Executives and directors of Hims & Hers Health Inc., a leading telehealth company, are facing a shareholder derivative ...
Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results